scholarly journals Emerging Frontiers of Therapeutic Strategies for Brain Tumors: A NeuroMolecular Medicine Special Issue

2022 ◽  
Author(s):  
Vishwanath R. Iyer ◽  
John S. Kuo
Keyword(s):  
Brain Tumors ◽  
Therapeutic Strategies ◽  
Special Issue

scholarly journals Proceedings of the GDR Vertige 2019 annual meeting devoted to endolymphatic hydrops

2021 ◽  
pp. 1-3
Author(s):  
Christian Chabbert ◽  
Anne Charpiot
Keyword(s):  
Annual Meeting ◽  
Research Group ◽  
Endolymphatic Hydrops ◽  
Clinical Manifestations ◽  
Vestibular Function ◽  
Therapeutic Strategies ◽  
Vestibular Disorders ◽  
Special Issue ◽  
Clinical Imaging ◽  
New Methods

The GDR Vertige is a federative research group gathering the different components of the French neuro-otology community. The annual meeting of the GDR Vertige is an opportunity for interactive exchanges between scientists, clinicians and industrialists, on basic issues related to vestibular function, as well as translational questions regarding the management of vestibular disorders. For its fifth edition, the annual meeting of the GDR Vertige, which took place in September 2019 in Marseille (France), was devoted to one of the most peculiar phenomena of neuro-otology: endolymphatic hydrops. For two days, international scientists and clinicians presented the most recent advances regarding the biophysical correlates of endolymphatic hydrops, the genetic and endocrine tableaux that favor its manifestation, new methods of clinical imaging, and current and upcoming therapeutic strategies to overcome the associated clinical manifestations. This special issue of the Journal of Vestibular Research aims at providing the proceedings of this meeting.

Exploring and Exploiting Tissue Engineering Through the Design of Multifunctional Therapeutic Systems

2019 ◽  
Vol 14 (2) ◽  
pp. 80-82 ◽  
Author(s):  
Masoud Mozafari
Keyword(s):  
Tissue Engineering ◽  
Stem Cell ◽  
Regenerative Medicine ◽  
Stem Cell Research ◽  
Therapeutic Strategies ◽  
Common Theme ◽  
Special Issue ◽  
The Common ◽  
Lead Article

This article presents a special issue of "Current Stem Cell Research & Therapy" devoted to exploring and exploiting tissue engineering through the design of multifunctional therapeutic systems. This lead article draws from twelve contributed articles to discuss the most recent advancements in this emerging field. The common theme in the contributed articles is the emerging therapeutic strategies, and a special appeal is made for collaboration between engineers and biologists for the development of multifunctional therapeutic systems for tissue engineering and regenerative medicine.

scholarly journals Novel Targets and Therapeutic Strategies for Promoting Organ Repair and Regeneration

Biomolecules ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. 749
Author(s):  
Shanmugam Muruganandan ◽  
Michael Wigerius
Keyword(s):  
Stem Cell ◽  
Regenerative Medicine ◽  
Drug Administration ◽  
Treatment Options ◽  
Therapeutic Strategies ◽  
Clinical Settings ◽  
Special Issue ◽  
Organ Repair ◽  
Novel Targets ◽  
New Treatment

Strategies to create functional organs and tissues is of great interest for use in regenerative medicine in order to repair or replace the lost tissues due to injury, disease, as well as aging. Several new treatment options, including stem cell treatments and tissue-engineered substitutes for certain indications, have been approved by Food and Drug Administration (FDA) and are currently available. This special issue will cover new therapies and strategies that are currently being investigated under preclinical and clinical settings.

Combinatorial Therapeutic Strategies for Blocking Kinase Pathways in Brain Tumors

CNS Cancer ◽  
2009 ◽  
pp. 953-975
Author(s):  
Paul H. Huang ◽  
Forest M. White
Keyword(s):  
Brain Tumors ◽  
Therapeutic Strategies

Possibilities of new therapeutic strategies in brain tumors

2010 ◽  
Vol 36 (4) ◽  
pp. 335-341 ◽  
Author(s):  
Eric Bouffet ◽  
Uri Tabori ◽  
Annie Huang ◽  
Ute Bartels
Keyword(s):  
Brain Tumors ◽  
Therapeutic Strategies

scholarly journals P13.14 Use of Foundation one CDx for molecular screening in patients with primary brain tumors: Gustave Roussy Experience

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii65-iii65
Author(s):  
C Baldini ◽  
W Boulfoul ◽  
L Lacroix ◽  
E Rouleau ◽  
J Scoazec ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Brain Tumors ◽  
Tumor Tissue ◽  
Therapeutic Strategies ◽  
Braf V600e ◽  
Tumor Type ◽  
Molecular Screening ◽  
Primary Brain Tumors ◽  
Molecular Alterations ◽  
Multidisciplinary Meeting

Abstract BACKGROUND Patients with primary brain tumors usually have poor prognosis and few therapeutic options. However recent report showed that they may benefit from molecular screening to improve treatment benefit and enrollment in clinical trials. We aimed to evaluate if molecular screening using Foundation One Dx may help therapeutic strategies in primary brain tumor patients. MATERIAL AND METHODS Between October 2018 and December 2018, we enrolled prospectively patients in the MOSCATO (Molecular Screening for cancer Treatment Optimization) 02 trial using the Foundation One Dx test. Patients were eligible if they had good Performans status (PS) (0 or 1) and tumor tissue material available. Results were reviewed during a molecular multidisciplinary meeting weekly at the Drug Development Department at Gustave Roussy to decide on orientation and matched therapy according to molecular alterations. RESULTS Finally thirty-three patients were enrolled in the study. Twenty six tumor tissues were analysed and 7 patients were screen failures due to tumor tissue unavailability. Median age was 49 years old (19 - 72). Patients had a good PS with a median of 1 (0–2) and were mostly males (76%). The most common tumor type was glioblastoma (79%). Five patients had a high grade tumor including 2 medulloblastomas. Median time between consent and multidisciplinary meeting was 70 days (49 - 156). Median percentage of tumor cells was 78% (30–80%). The tumor mutational burden (TMB) was available in 26 patients. The median TMB was 4 mutations per megabase (0 - 277). The most frequent alterations were TERT promoter mutation 22/26 (85%), CDKN2A loss 14/26 (54%), MTAP loss 11/26 (42%), EGFR amplification (38%) including 4 EGFRvIII amplification, TP53 mutation and PTEN deletion 9/26 (35%) respectively, PIK3CA mutation 5/26 (19%), CDK4 or 6 amplification 4/26 (15%), NF1 mutation 3/26 (12%), 2 IDH1 mutations, 2 MET amplifications, 2 HGF amplifications, 1 FGFR2 mutation, 1 BRAF V600E mutation, 1 PDGFRA amplification, 1 EZH2 mutation and 1 SMARCA4 mutation. Finally 11 patients (42%) were oriented according to molecular alterations (EGFR amplifications, BRAF mutation), 1 patient was treated and is ongoing with a BRAF inhibitor and 1 patient is in screening in atrial with an EGFR inhibitor. CONCLUSION Molecular screening with Foundation One Dx test is feasible in patients with primary brain tumors and can help therapeutic strategies. However the time between consent and multidisciplinary meeting was the main limitation to our study and affected enrollment in clinical trials.

scholarly journals Identification of Disease Risk DNA Variations is Shaping the Future of Precision Health

Genes ◽  
2019 ◽  
Vol 10 (6) ◽  
pp. 450
Author(s):  
Walid D. Fakhouri ◽  
Ariadne Letra
Keyword(s):  
Developmental Disorders ◽  
Disease Risk ◽  
Genetic Research ◽  
Therapeutic Strategies ◽  
Special Issue ◽  
Disease States ◽  
Genomic Architecture ◽  
Dna Variations ◽  
Precision Health ◽  
Over Time

In recent years, the knowledge generated by decoding the human genome has allowed groundbreaking genetic research to better understand genomic architecture and heritability in healthy and disease states. The vast amount of data generated over time and yet to be generated provides the basis for translational research towards the development of preventive and therapeutic strategies for many conditions. In this special issue, we highlight the discoveries of disease-associated and protective DNA variations in common human diseases and developmental disorders.

Sign in / Sign up

Export Citation Format

Share Document